Literature DB >> 9720505

Determinants of villous trophoblastic hyperplasia in spontaneous abortions.

R W Redline1, T Hassold, M Zaragoza.   

Abstract

The diagnosis of complete and partial mole with its subsequent risk of trophoblastic malignancy relies on histologic criteria that are sometimes seen in nonmolar conceptuses. We performed karyotypic analysis on 1054 spontaneous abortions during a 43-month period. Villous trophoblastic hyperplasia was graded from 0 to 3 in successfully karyotyped cases of complete mole, triploidy, tetraploidy, monosomy X, trisomy, normal 46,XY, and normal 46,XX without contaminating maternal tissues (n = 649). Parental origin of the extra chromosome was analyzed by polymerase chain reaction in 64 trisomic cases. We also evaluated for each case the developmental stage, presence of uniformly hydropic villi, amnion, villous nucleated red blood cells, and fetal tissue. Villous trophoblastic hyperplasia was increased in spontaneous abortions with abnormal karyotype as a group and in the subgroup with trisomy compared with those of a normal karyotype. Hyperplasia and particularly high-grade hyperplasia (Grades 2-3), equivalent in severity to that seen in proliferative partial and complete moles was most frequent in a subgroup of trisomies involving chromosomes 7 (60% hyperplasia, with 30% of high grade), 15 (50% hyperplasia, 15% high grade), 21 (22% hyperplasia, 11% high grade), and 22 (13% hyperplasia, 4% high grade). Frequency of paternal origin for the extra chromosome in these four trisomies was similar in cases with and without hyperplasia There was a nonsignificant increase in female sex chromosomes with hyperplasia in both trisomic and normal conceptuses. Hyperplasia was more common in trisomic abortions of late stage (> 8.5 wk, P = .013), in those that lacked uniformly hydropic villi (P < .001), and in those that lacked fetal tissue (P = .204). This latter phenotype was particularly common with trisomies 15, 21, and 22.

Entities:  

Mesh:

Year:  1998        PMID: 9720505

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

1.  Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis.

Authors:  Russell Vang; Mamta Gupta; Lee-Shu-Fune Wu; Anna V Yemelyanova; Robert J Kurman; Kathleen M Murphy; Cheryl Descipio; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2012-03       Impact factor: 6.394

2.  Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis for both recently trained and experienced gynecologic pathologists.

Authors:  Mamta Gupta; Russell Vang; Anna V Yemelyanova; Robert J Kurman; Fanghong Rose Li; Emily C Maambo; Kathleen M Murphy; Cheryl DeScipio; Carol B Thompson; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

Review 3.  Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine.

Authors:  Natalia Buza; Pei Hui
Journal:  Mod Pathol       Date:  2021-06-04       Impact factor: 7.842

4.  Refined diagnosis of hydatidiform moles with p57 immunohistochemistry and molecular genotyping: updated analysis of a prospective series of 2217 cases.

Authors:  Deyin Xing; Emily Adams; Jialing Huang; Brigitte M Ronnett
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

5.  Loss of p57 Expression in Conceptions Other Than Complete Hydatidiform Mole: A Case Series With Emphasis on the Etiology, Genetics, and Clinical Significance.

Authors:  Deyin Xing; Karin Miller; Katie Beierl; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2022-01-01       Impact factor: 6.298

6.  Abnormal villous morphology mimicking a hydatidiform mole associated with paternal trisomy of chromosomes 3,7,8 and unipaternal disomy of chromosome 11.

Authors:  Neil J Sebire; Philippa C May; Baljeet Kaur; Michael J Seckl; Rosemary A Fisher
Journal:  Diagn Pathol       Date:  2016-02-04       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.